Skip to main content
Blog

Meta-Analysis: ePRO Compliance and Retention for Patients Using Their Own Smartphones in Fully Decentralized Clinical Trials

Download the PDF

‍Susan M. Dallabrida PhD, Matty Culberth-Notaro BSN-RN 

‍

Objective

Traditionally, electronic patient-reported outcomes (ePRO) were collected on provisioned devices provided by clinical sites. Patient retention in clinical trials depended largely on the sites’ ability to engage patients during visits. The arrival of “bring your own device” (BYOD) models has enabled patients to complete ePRO in clinical trials using their own smartphones. There has been considerable speculation in the industry as to how such a model would impact study retention and ePRO task completion. Herein, we show the results from a meta-analysis of six (6) clinical trials across therapeutic areas in which patients completed diaries using their own smartphones.

‍

Method

Patients completed daily ePRO assessments between 2018 and 2021 using the ObvioHealth app on their personal smartphones (Android or iOS) in therapeutic areas that included: urinary incontinence, dermatology, lower urinary tract symptoms, menopause, hypertension, and infant nutrition. 

‍

Results

Study durations ranged from 4 to 19 months, with an average study period of 10.5 +5.7 months. In total, 752 patients were enrolled with 658 patients completing their respective study. The overall retention rate across the six studies was 88%. The average weighted ePRO compliance was 90% across the six studies. 
‍

Conclusion

In summary, these data show that retention of study patients in a fully decentralized clinical trial is relatively high at 88% compared to the traditional site-based industry benchmark of 70%. Similarly, ePRO compliance of 90% suggests that patients are willing and able to use their personal smartphones to remain engaged with and compliant in a clinical trial. It is surmised that in addition to a user-friendly app, automatic notifications and a live virtual clinical support team regularly in contact with participants to encourage engagement and retention are critical factors in achieving these improvements.

Blog

Meta-Analysis: ePRO Compliance and Retention for Patients Using Their Own Smartphones in Fully Decentralized Clinical Trials

No items found.
Download the PDF

‍Susan M. Dallabrida PhD, Matty Culberth-Notaro BSN-RN 

‍

Objective

Traditionally, electronic patient-reported outcomes (ePRO) were collected on provisioned devices provided by clinical sites. Patient retention in clinical trials depended largely on the sites’ ability to engage patients during visits. The arrival of “bring your own device” (BYOD) models has enabled patients to complete ePRO in clinical trials using their own smartphones. There has been considerable speculation in the industry as to how such a model would impact study retention and ePRO task completion. Herein, we show the results from a meta-analysis of six (6) clinical trials across therapeutic areas in which patients completed diaries using their own smartphones.

‍

Method

Patients completed daily ePRO assessments between 2018 and 2021 using the ObvioHealth app on their personal smartphones (Android or iOS) in therapeutic areas that included: urinary incontinence, dermatology, lower urinary tract symptoms, menopause, hypertension, and infant nutrition. 

‍

Results

Study durations ranged from 4 to 19 months, with an average study period of 10.5 +5.7 months. In total, 752 patients were enrolled with 658 patients completing their respective study. The overall retention rate across the six studies was 88%. The average weighted ePRO compliance was 90% across the six studies. 
‍

Conclusion

In summary, these data show that retention of study patients in a fully decentralized clinical trial is relatively high at 88% compared to the traditional site-based industry benchmark of 70%. Similarly, ePRO compliance of 90% suggests that patients are willing and able to use their personal smartphones to remain engaged with and compliant in a clinical trial. It is surmised that in addition to a user-friendly app, automatic notifications and a live virtual clinical support team regularly in contact with participants to encourage engagement and retention are critical factors in achieving these improvements.

Blog

Meta-Analysis: ePRO Compliance and Retention for Patients Using Their Own Smartphones in Fully Decentralized Clinical Trials

No items found.
Download the PDF

‍Susan M. Dallabrida PhD, Matty Culberth-Notaro BSN-RN 

‍

Objective

Traditionally, electronic patient-reported outcomes (ePRO) were collected on provisioned devices provided by clinical sites. Patient retention in clinical trials depended largely on the sites’ ability to engage patients during visits. The arrival of “bring your own device” (BYOD) models has enabled patients to complete ePRO in clinical trials using their own smartphones. There has been considerable speculation in the industry as to how such a model would impact study retention and ePRO task completion. Herein, we show the results from a meta-analysis of six (6) clinical trials across therapeutic areas in which patients completed diaries using their own smartphones.

‍

Method

Patients completed daily ePRO assessments between 2018 and 2021 using the ObvioHealth app on their personal smartphones (Android or iOS) in therapeutic areas that included: urinary incontinence, dermatology, lower urinary tract symptoms, menopause, hypertension, and infant nutrition. 

‍

Results

Study durations ranged from 4 to 19 months, with an average study period of 10.5 +5.7 months. In total, 752 patients were enrolled with 658 patients completing their respective study. The overall retention rate across the six studies was 88%. The average weighted ePRO compliance was 90% across the six studies. 
‍

Conclusion

In summary, these data show that retention of study patients in a fully decentralized clinical trial is relatively high at 88% compared to the traditional site-based industry benchmark of 70%. Similarly, ePRO compliance of 90% suggests that patients are willing and able to use their personal smartphones to remain engaged with and compliant in a clinical trial. It is surmised that in addition to a user-friendly app, automatic notifications and a live virtual clinical support team regularly in contact with participants to encourage engagement and retention are critical factors in achieving these improvements.

Blog

Meta-Analysis: ePRO Compliance and Retention for Patients Using Their Own Smartphones in Fully Decentralized Clinical Trials

No items found.
Download the PDF

‍Susan M. Dallabrida PhD, Matty Culberth-Notaro BSN-RN 

‍

Objective

Traditionally, electronic patient-reported outcomes (ePRO) were collected on provisioned devices provided by clinical sites. Patient retention in clinical trials depended largely on the sites’ ability to engage patients during visits. The arrival of “bring your own device” (BYOD) models has enabled patients to complete ePRO in clinical trials using their own smartphones. There has been considerable speculation in the industry as to how such a model would impact study retention and ePRO task completion. Herein, we show the results from a meta-analysis of six (6) clinical trials across therapeutic areas in which patients completed diaries using their own smartphones.

‍

Method

Patients completed daily ePRO assessments between 2018 and 2021 using the ObvioHealth app on their personal smartphones (Android or iOS) in therapeutic areas that included: urinary incontinence, dermatology, lower urinary tract symptoms, menopause, hypertension, and infant nutrition. 

‍

Results

Study durations ranged from 4 to 19 months, with an average study period of 10.5 +5.7 months. In total, 752 patients were enrolled with 658 patients completing their respective study. The overall retention rate across the six studies was 88%. The average weighted ePRO compliance was 90% across the six studies. 
‍

Conclusion

In summary, these data show that retention of study patients in a fully decentralized clinical trial is relatively high at 88% compared to the traditional site-based industry benchmark of 70%. Similarly, ePRO compliance of 90% suggests that patients are willing and able to use their personal smartphones to remain engaged with and compliant in a clinical trial. It is surmised that in addition to a user-friendly app, automatic notifications and a live virtual clinical support team regularly in contact with participants to encourage engagement and retention are critical factors in achieving these improvements.

Blog

Meta-Analysis: ePRO Compliance and Retention for Patients Using Their Own Smartphones in Fully Decentralized Clinical Trials

No items found.
Download the PDF

‍Susan M. Dallabrida PhD, Matty Culberth-Notaro BSN-RN 

‍

Objective

Traditionally, electronic patient-reported outcomes (ePRO) were collected on provisioned devices provided by clinical sites. Patient retention in clinical trials depended largely on the sites’ ability to engage patients during visits. The arrival of “bring your own device” (BYOD) models has enabled patients to complete ePRO in clinical trials using their own smartphones. There has been considerable speculation in the industry as to how such a model would impact study retention and ePRO task completion. Herein, we show the results from a meta-analysis of six (6) clinical trials across therapeutic areas in which patients completed diaries using their own smartphones.

‍

Method

Patients completed daily ePRO assessments between 2018 and 2021 using the ObvioHealth app on their personal smartphones (Android or iOS) in therapeutic areas that included: urinary incontinence, dermatology, lower urinary tract symptoms, menopause, hypertension, and infant nutrition. 

‍

Results

Study durations ranged from 4 to 19 months, with an average study period of 10.5 +5.7 months. In total, 752 patients were enrolled with 658 patients completing their respective study. The overall retention rate across the six studies was 88%. The average weighted ePRO compliance was 90% across the six studies. 
‍

Conclusion

In summary, these data show that retention of study patients in a fully decentralized clinical trial is relatively high at 88% compared to the traditional site-based industry benchmark of 70%. Similarly, ePRO compliance of 90% suggests that patients are willing and able to use their personal smartphones to remain engaged with and compliant in a clinical trial. It is surmised that in addition to a user-friendly app, automatic notifications and a live virtual clinical support team regularly in contact with participants to encourage engagement and retention are critical factors in achieving these improvements.

Blog

Meta-Analysis: ePRO Compliance and Retention for Patients Using Their Own Smartphones in Fully Decentralized Clinical Trials

Download the PDF
No items found.

‍Susan M. Dallabrida PhD, Matty Culberth-Notaro BSN-RN 

‍

Objective

Traditionally, electronic patient-reported outcomes (ePRO) were collected on provisioned devices provided by clinical sites. Patient retention in clinical trials depended largely on the sites’ ability to engage patients during visits. The arrival of “bring your own device” (BYOD) models has enabled patients to complete ePRO in clinical trials using their own smartphones. There has been considerable speculation in the industry as to how such a model would impact study retention and ePRO task completion. Herein, we show the results from a meta-analysis of six (6) clinical trials across therapeutic areas in which patients completed diaries using their own smartphones.

‍

Method

Patients completed daily ePRO assessments between 2018 and 2021 using the ObvioHealth app on their personal smartphones (Android or iOS) in therapeutic areas that included: urinary incontinence, dermatology, lower urinary tract symptoms, menopause, hypertension, and infant nutrition. 

‍

Results

Study durations ranged from 4 to 19 months, with an average study period of 10.5 +5.7 months. In total, 752 patients were enrolled with 658 patients completing their respective study. The overall retention rate across the six studies was 88%. The average weighted ePRO compliance was 90% across the six studies. 
‍

Conclusion

In summary, these data show that retention of study patients in a fully decentralized clinical trial is relatively high at 88% compared to the traditional site-based industry benchmark of 70%. Similarly, ePRO compliance of 90% suggests that patients are willing and able to use their personal smartphones to remain engaged with and compliant in a clinical trial. It is surmised that in addition to a user-friendly app, automatic notifications and a live virtual clinical support team regularly in contact with participants to encourage engagement and retention are critical factors in achieving these improvements.

Back to Top
Blog

Meta-Analysis: ePRO Compliance and Retention for Patients Using Their Own Smartphones in Fully Decentralized Clinical Trials

Download the PDF

‍Susan M. Dallabrida PhD, Matty Culberth-Notaro BSN-RN 

‍

Objective

Traditionally, electronic patient-reported outcomes (ePRO) were collected on provisioned devices provided by clinical sites. Patient retention in clinical trials depended largely on the sites’ ability to engage patients during visits. The arrival of “bring your own device” (BYOD) models has enabled patients to complete ePRO in clinical trials using their own smartphones. There has been considerable speculation in the industry as to how such a model would impact study retention and ePRO task completion. Herein, we show the results from a meta-analysis of six (6) clinical trials across therapeutic areas in which patients completed diaries using their own smartphones.

‍

Method

Patients completed daily ePRO assessments between 2018 and 2021 using the ObvioHealth app on their personal smartphones (Android or iOS) in therapeutic areas that included: urinary incontinence, dermatology, lower urinary tract symptoms, menopause, hypertension, and infant nutrition. 

‍

Results

Study durations ranged from 4 to 19 months, with an average study period of 10.5 +5.7 months. In total, 752 patients were enrolled with 658 patients completing their respective study. The overall retention rate across the six studies was 88%. The average weighted ePRO compliance was 90% across the six studies. 
‍

Conclusion

In summary, these data show that retention of study patients in a fully decentralized clinical trial is relatively high at 88% compared to the traditional site-based industry benchmark of 70%. Similarly, ePRO compliance of 90% suggests that patients are willing and able to use their personal smartphones to remain engaged with and compliant in a clinical trial. It is surmised that in addition to a user-friendly app, automatic notifications and a live virtual clinical support team regularly in contact with participants to encourage engagement and retention are critical factors in achieving these improvements.

Discover More Case Studies

Discover More News

Discover More White Papers

Discover More Blogs

Discover More Playbooks

Discover More Webinars

Discover More Events

No items found.

eConsent and the FDA: Implications of New Draft Guidance

The FDA and OHRP have released new draft guidance providing recommendations for making the informed consent process as clear and comprehensive as possible for participants. Here's what you need to know.

› Read More
No items found.

Patient-Reported Outcomes: Essential Data for Every Clinical Trial's Outcome Measure

Patient-reported outcomes are crucial components of every clinical trial—and they’re stronger and more accurate when captured electronically. Here’s what you need to know about PROs and ePROs.

› Read More